To evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae (access sites used for dialysis) in a real-world scenario.

To evaluate the safety and performance of the Xeltis hemodialysis access graft in subjects older than 18 years with end stage renal disease (ESRD) and possessing an estimated glomerular filtration rate (eGFR) less than 20 ml/min.